Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase
Proceedings of the National Academy of Sciences · 13.02.2024 · 121 (7)
DOI: 10.1073/pnas.2314085121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.02.2024. Verfasst von Abigail G Kelly und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS.
Abstract (Originalsprache)
Cancer therapy, including immunotherapy, is inherently limited by chronic inflammation-induced tumorigenesis and toxicity within the tumor microenvironment. Thus, stimulating the resolution of inflammation may enhance immunotherapy and improve the toxicity of immune checkpoint inhibition (ICI). As epoxy-fatty acids (EpFAs) are degraded by the enzyme soluble epoxide hydrolase (sEH), the inhibition of sEH increases endogenous EpFA levels to promote the resolution of cancer-associated inflammation. Here, we demonstrate that systemic treatment with ICI induces sEH expression in multiple murine cancer models. Dietary omega-3 polyunsaturated fatty acid supplementation and pharmacologic sEH inhibition, both alone and in combination, significantly enhance anti-tumor activity of ICI in these models. Notably, pharmacological abrogation of the sEH pathway alone or in combination with ICI counter-regulates an ICI-induced pro-inflammatory and pro-tumorigenic cytokine storm. Thus, modulating endogenous EpFA levels through dietary supplementation or sEH inhibition may represent a unique strategy to enhance the anti-tumor activity of paradigm cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
- Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
- Department of Entomology and Nematology, University of California, Davis, CA 95616.
- University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817.
- Department of Food Science, Purdue University, West Lafayette, IN 47907.
ORCID-Profile: Jun Yang, Molly M Gilligan, Bruce D Hammock
Förderung
- NIEHS NIH HHS
Zitieren
APA
Kelly, A. G., Wang, W., Rothenberger, E., Yang, J., Gilligan, M. M., Kipper, F. C., Attaya, A., Gartung, A., Hwang, S. H., Gillespie, M. J., Bayer, R. L., Quinlivan, K. M., Torres, K. L., Huang, S., Mitsiades, N., Yang, H., Hammock, B. D., & Panigrahy, D. (2024). Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase. Proceedings of the National Academy of Sciences, 121(7). https://doi.org/10.1073/pnas.2314085121
Vancouver
Kelly AG, Wang W, Rothenberger E, Yang J, Gilligan MM, Kipper FC, et al. Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase. Proceedings of the National Academy of Sciences. 2024;121(7). doi:10.1073/pnas.2314085121
BibTeX
@article{Kelly2024,
author = {Kelly, Abigail G and Wang, Weicang and Rothenberger, Eva and Yang, Jun and Gilligan, Molly M and Kipper, Franciele C and Attaya, Ahmed and Gartung, Allison and Hwang, Sung Hee and Gillespie, Michael J and Bayer, Rachel L and Quinlivan, Katherine M and Torres, Kimberly L and Huang, Sui and Mitsiades, Nicholas and Yang, Haixia and Hammock, Bruce D and Panigrahy, Dipak},
title = {Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {7},
doi = {10.1073/pnas.2314085121}
}
EUVIMED